@article{9c6ee89d4f644a6da31b49de09c1d7c6,
title = "Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies",
keywords = "metastatic renal cell carcinoma, preventive cardiology, tyrosine kinase inhibitors",
author = "Avirup Guha and Nicolas Sayegh and Neeraj Agarwal",
note = "Funding Information: Dr Guha is supported by the American Heart Association Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (847740 and 863620). Dr Agarwal is a consultant to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; and has received institutional research funding from Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Dr Sayegh has reported that he has no relationships relevant to the contents of this paper to disclose.",
year = "2022",
month = jun,
doi = "10.1016/j.jaccao.2022.05.007",
language = "English (US)",
volume = "4",
pages = "235--237",
journal = "JACC: CardioOncology",
issn = "2666-0873",
publisher = "Elsevier Inc.",
number = "2",
}